[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obsessive-compulsive-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obsessive-compulsive-disorder":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,82,0,25,[9,43,80,113,143,170,195,219,243,265,292,335,361,382,403,428,447,468,496,514,537,563,591,617,640],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100510859","tms--exposure-therapy-for-pediatric-ocd-100510859",false,"NCT05931913","TMS + Exposure Therapy for Pediatric OCD","Transcranial Magnetic Stimulation to Augment Exposure and Response Prevention for Pediatric OCD","NExT","Inclusion Criteria:\n\n* Between the ages of 12 and 21 years.\n* Presence of OCD, as indicated by a score of \\> 16 on the Children's Yale-Brown Obsessive Compulsive Scale, indicating moderate or greater OCD symptoms.\n* Presence of motor compulsions on CY-BOCS compulsion checklist\n* English fluency to ensure comprehension of informed consent and study measures and instructions.\n\nExclusion Criteria:\n\n* Decline to provide informed consent.\n* Has a personal history, or a family history in a first-born relative, of any medical or psychiatric disorder, disease, condition, injury, symptoms or circumstance that, in the opinion of the principal investigator, may: (1) impact the risk profile of TMS; (2) reduce the subject's ability to fulfill the study requirements as per protocol; or (3) adversely impact the integrity of the data or the validity of the study results.\" Some examples include: epilepsy or seizure disorder(s), bipolar disorder or any psychiatric disorder associated with a risk of mania, intracranial pathology, traumatic brain injury, brain tumor, stroke, implanted medical devices or metallic objects in the head, or moderate-severe heart disease\n* Pregnant according to the medical history or a urine pregnancy test; and menstruating females who are heterosexually active and not using a highly effective form of contraception (tubal ligation, FDA-approved hormonal contraceptive, or an IUD)\n* Inability to undergo MRI.\n* Left handedness.\n* Is deemed to be at imminent risk of suicide according to the Ask Suicide-Screening Questions (ASQ) (i.e. answers YES to ≥ one (1) of the four screening questions) and\u002For in the medical opinion of the investigator\n* History of, or risk factors for, neurocardiogenic syncope (history of syncope\u002F presyncope related to noxious stimuli, anxiety, micturation, or posture).\n* Concurrent psychotherapy of any kind for OCD.\n* Concurrent TMS or receipt of any TMS experimental or clinical treatment less than 3 months prior to enrollment.\n* Taking a medication deemed to pose high seizurogenic potential per physician review\n* Taking a medication that has not reached stability criterion (same medication and dose for 6 weeks with no planned changes over the study period)","ALL","12 Years","21 Years",{"count":22,"type":23},60,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this clinical trial is to compare different forms of transcranial magnetic stimulation (TMS) for improving the outcomes of Exposure with Response Prevention (ERP) in youth and young adults with Obsessive-Compulsive Disorder (OCD). Researchers will compare three groups: ERP with one of two different active (\"real\") forms of TMS vs. ERP with sham (\"fake\") TMS. The main questions this study aims to answer are: 1) whether TMS normalizes functioning in brain circuits that contribute to compulsive behavior, and 2) whether TMS reduces compulsions during ERP. Participants will:\n\n* Complete clinical interviews, questionnaires, and computerized tasks\n* Complete two MRIs (brain scans)\n* Receive daily TMS followed by ERP for two weeks (10 sessions)",[29],"Obsessive-Compulsive Disorder","RECRUITING","2026-08-19",{"date":33,"type":34},"2026-08-21","ACTUAL",{"date":36,"type":34},"2024-03-20",{"date":38,"type":23},"2029-10-31",{"name":40,"class":41},"Bradley Hospital","OTHER",2,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":62,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100410940","developing-brain-impulsivity-and-compulsivity-100410940","NCT04631042","Developing Brain, Impulsivity and Compulsivity","An Observational Study of the Developing Brain, Impulsivity and Compulsivity","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study.\n2. Must be between 6 and 80 years of age.\n3. Ability of participant to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Cognitively not capable of performing study procedures or lack of capacity to provide informed consent. Indications of a lack of cognitive capacity could include a known full-scale IQ under 70, or a history from the screening interview that implies global intellectual disabilities (e.g., placement in a school for children with intellectual disability etc.)\n2. Very premature birth (i.e., birth before 32 weeks of gestational age).\n3. Any known brain abnormalities (e.g., tumor, periventricular leukomalacia, microcephaly) or history of medical conditions known to affect cerebral anatomy (e.g., epilepsy, history of stroke, head injury with a loss of consciousness of one hour or more).\n4. Psychotic disorders (including schizophrenia, psychosis not otherwise specified).\n5. Dementia, or other conditions that, in the opinion of the investigators, would impede compliance or possibly hinder completion of the study.\n6. Pregnant women.\n7. Any other medical or psychiatric condition that in the opinion of the PI may confound study data\u002Fassessments.\n\nAdditional exclusion criteria for optional MRI procedure:\n\n1\\. Individuals who are not able to receive an MRI (e.g., metal bioimplants, claustrophobia, inability to lie flat on their backs, pregnant women, and any other contraindications for MRI scanning according to the NMR Center MRI safety guidelines).","6 Years","80 Years",{"count":53,"type":23},1100,"OBSERVATIONAL","Background:\n\nImpulsivity is acting 'without thinking.' Compulsivity is being overly inflexible. People vary in how impulsive or compulsive they are. Extreme versions of these behaviors play a role in mental disorders. Researchers want to study changes in the brain to learn more about these behaviors. Differences in genes may also play a role.\n\nObjective:\n\nTo learn about genetic \\& brain features that explain why levels of impulsivity and compulsivity vary across people.\n\nEligibility:\n\nPeople ages 6 - 80\n\nDesign:\n\nParticipants will be screened with a medical history and medical record review.\n\nParticipants will talk about their mental and behavioral development. They may discuss topics like drug use and sexual activity. They will complete surveys about their compulsivity and impulsivity. Parents of child participants may also complete these surveys.\n\nParticipants may take memory, attention, and thinking tests. They may give blood or saliva samples for gene studies and they may give blood to make induced pluripotent stem cells. Participants may have their face and irises photographs taken.\n\nParticipants may have a magnetic resonance imaging scan. It will take pictures of their brain. The scanner is shaped like a cylinder. Participants will lie on a table that slides in and out of the scanner. A coil will be placed over their head. They will lie still, watch a movie, and play a game.\n\nParticipants may ask family members to join the study. Researchers are particularly interested in recruiting twin pairs to the study.\n\nParticipants under age 25 may repeat these tests every 1-2 years until they turn 25 or until the study ends. For those over age 25, participation will last less than 1 month.",[57,58,59,60,61],"Typical Development","Obsessive Compulsive Disorder","Conduct Disorder","Attention Deficit Hyperactivity Disorder","Autism Spectrum Disorder",[63,64,65,66,67,68,69],"Neurodevelopmental disorder","Twin","Natural History","Heritability","Glutamate","developmental trajectory","Brain Connectivity","2026-08-18",{"date":31,"type":34},{"date":73,"type":34},"2022-09-30",{"date":75,"type":23},"2031-12-31",{"name":77,"class":78},"National Institute of Mental Health (NIMH)","NIH",1,{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":18,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":24,"phases":90,"briefSummary":91,"conditions":92,"keywords":101,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":79},"100652361","anxiety-skills-study-100652361","NCT07774481","Anxiety Skills Study","Personalizing and Optimizing CBT Skills for Anxiety","Inclusion Criteria:\n\n* Presence of clinically elevated anxiety\n* Living in Ohio\n\nExclusion Criteria:\n\n* No access to a smartphone\n* Presence of conditions that would necessitate alternative care","18 Years",{"count":89,"type":23},600,[26],"The purposes of this study are: (1) to identify baseline predictors of relative success in cognitive, behavioral, and mindfulness-based treatments for anxiety, (2) explore who benefits from a brief, video-based skill training compared to receiving 4 sessions of therapy, and (3) to evaluate how durable these effects are over 1 year.",[93,94,95,96,97,98,99,29,100],"Anxiety","Anxiety Acute","Anxiety Chronic","Anxiety and Mood Disorders","Social Anxiety Disorder","Panic Disorder (With or Without Agoraphobia)","Generalized Anxiety Disorder","Specific Phobia",[102,103,104],"anxiety","CBT","treatment","2026-08-17",{"date":31,"type":34},{"date":108,"type":34},"2025-10-20",{"date":110,"type":23},"2030-08-31",{"name":112,"class":41},"Ohio State University",{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":18,"minAge":87,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":24,"phases":124,"briefSummary":127,"conditions":128,"keywords":129,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":79},"100560279","phase-1-pilot-study-of-rr-hnk-in-ocd-100560279","NCT06575075","Pilot Study of RR-HNK in OCD","A Double-blind, Placebo-controlled Study to Determine the Safety and Feasibility of Two Doses of Intravenous (2R, 6R)-Hydroxynorketamine (RR-HNK) in Adults With Obsessive-Compulsive Disorder","(HNKO)","Inclusion Criteria:\n\n* Ages 18-65\n* Meet the criteria for OCD diagnosis\n* Failed at least 1 prior trial of standard first-line OCD treatment (e.g. SRI\u002FCBT) or or had refused these treatments for individual reasons\n* Agree to the following lifestyle modifications: comply with requirements for fasting prior to --the infusion session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures.\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to ketamine\n* Any current or past medical\u002Fpsychiatric condition that makes participation unsafe in the opinion of the investigator or study physician\n* Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control\n* Lifetime history of deep brain stimulation","65 Years",{"count":123,"type":23},45,[125,126],"PHASE1","PHASE2","The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.",[29],[130,131,132,133],"OCD","AMPA receptor antagonist","hydroxynorketamine","ketamine metabolite","2026-08-11",{"date":136,"type":34},"2026-08-12",{"date":138,"type":34},"2026-01-23",{"date":140,"type":23},"2029-11-30",{"name":142,"class":41},"Carolyn Rodriguez",{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":18,"minAge":87,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":24,"phases":154,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":79},"100468234","neural-mechanisms-of-response-inhibition-training-for-ocrd-100468234","NCT05377125","Neural Mechanisms of Response Inhibition Training for OCRD","Neural Mechanisms of Response Inhibition Training for Obsessive-Compulsive Disorder and Related Conditions","OCRD","Inclusion Criteria:\n\n* age between 18 and 60\n* moderate level of OCRD symptoms (Yale-Brown Obsessive Compulsive Scale total ≥ 16, Massachusetts General Hospital-Hair pulling Scale total ≥ 12, or Skin Picking Scale-Revised total ≥ 7)\n* a primary diagnosis of OCRD (i.e., OCD, TTM, or SPD)\n* estimated IQ \\> 80\n* presence of a RI deficits (SSRT ≥ 215ms).\n\nExclusion Criteria:\n\n* Current substance use disorder\n* Severe ADHD\n* Lifetime diagnosis of psychotic disorder, bipolar disorder, or schizophrenia\n* Current psychotherapy\n* Change in psychotropic medication status within 8 weeks before the study or during the study\n* Use of stimulant medication\n* Active suicidal risk\n* Contraindications for MRI procedures","60 Years",{"count":153,"type":23},118,[26],"The impaired ability to suppress an inappropriate but pre-potent response (response inhibition; RI) characterizes several debilitating clinical problems, including obsessive-compulsive and related disorders (OCRD) such as obsessive-compulsive disorder, trichotillomania, and skin picking disorder. There is a critical need to develop an effective and durable treatment for OCRDs with demonstrable evidence for improving impaired RI. The purpose of our project is to examine the impact of a novel computerized intervention, response inhibition training (RIT), on neural indices of RI, and examine the mechanistic link between engagement of the neural RI targets and change in OCRD symptoms. To this end, this project will conduct a randomized clinical trial for individuals with OCD, trichotillomania, and\u002For skin picking disorders. Participants will be randomly assigned to 8 to 16 sessions of computerized RIT or a computerized placebo training. Various clinical, behavioral, and brain-imaging data will be acquired to evaluate the training effects at baseline, post-training, and 1-month follow-up periods.",[29,157,158],"Tricholemmoma","Skin-Picking",[160],"OCD; Trichotillomania; Excoriation; Response Inhibition","2026-08-05",{"date":163,"type":34},"2026-08-10",{"date":165,"type":34},"2022-12-22",{"date":167,"type":23},"2027-08-31",{"name":169,"class":41},"University of Wisconsin, Milwaukee",{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":18,"minAge":176,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":24,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":79},"100486118","cbt-augmentation-to-promote-medication-discontinuation-in-pediatric-ocd-100486118","NCT05609916","CBT Augmentation to Promote Medication Discontinuation in Pediatric OCD","Inclusion Criteria:\n\n* The child is between the ages of 7 to 17 at enrollment with a primary diagnosis of OCD of \\> 6 months duration based on the Kiddie Schedule for Affective Disorders and Schizophrenia Lifetime Version for DSM-5 (KSADS-PL) and have a CY-BOCS ≥ 16.\n* The child is on stable and maximally tolerated SRI medication (i.e., clomipramine, fluoxetine, fluvoxamine, sertraline, citalopram, escitalopram) for ≥12 weeks given that they are persistently and moderately symptomatic. Paroxetine is exclusionary due to safety concerns.\n* Both the child and parent participating in the study are English speaking.\n* Both the child and their parent participating in the study reside in Texas.\n\nExclusion Criteria:\n\n* The child has a diagnosis of lifetime DSM-5 bipolar disorder, psychotic disorder, and\u002For intellectual disability.\n* The child has severe current suicidal\u002Fhomicidal ideation and\u002For self-injury requiring medical intervention.\n* The child is receiving concurrent psychotherapy for OCD.\n* Initiation of a psychotropic medication less than 4 weeks prior to study enrollment or a stimulant\u002Fpsychoactive medication less than 2 weeks prior to study enrollment.","7 Years","17 Years",{"count":179,"type":23},200,[26],"The purpose of this study is to examine whether youth with OCD who benefit from CBT augmentation to SRI can discontinue their medication without relapse over 24 weeks.",[183,29,184,185],"Cognitive Behavioral Therapy","Obsessive-Compulsive Disorder in Children","Obsessive-Compulsive Disorder in Adolescence","2026-08-03",{"date":188,"type":34},"2026-08-04",{"date":190,"type":34},"2022-11-30",{"date":192,"type":23},"2027-08-30",{"name":194,"class":41},"Baylor College of Medicine",{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":201,"sex":18,"minAge":176,"maxAge":177,"enrollmentInfo":202,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":79},"100574056","pathogenesis-of-pediatric-obsessive-compulsive-disorder-based-on-the-microbiota-gut-brain-axis-100574056","NCT06754319","Pathogenesis of Pediatric Obsessive-compulsive Disorder: Based on the Microbiota-gut-brain Axis","We recruited outpatient children and adolescents with OCD confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (4th edition). The following inclusion and exclusion criteria were also applied:\n\nInclusion Criteria:\n\n(1) 7-17 years old, (2) Y-BOCS score ≥16, (3) with or without a history of TD, (4) Drug-naïve or drug-free for 8 weeks, (5) Wechsler IQ score ≥ 80.\n\nExclusion Criteria:\n\n* History of serious medical, neurological illness or other psychotic disorders other than OCD (tic disorder excepted).\n* Previous exposure to cognitive behavioral therapy (CBT) for OCD or TD.\n* serious suicide risk.\n* Has taken antibiotics, probiotics, prebiotics, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or immunosuppressants within the past 8 weeks.\n* Has a history of gastrointestinal diseases such as inflammatory bowel disease, irritable bowel syndrome, constipation, hemorrhoids, or a history of gastrointestinal surgery, or has a history of autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus.\n* Participants with claustrophobic, heart pacemaker, mechanical heart valve, mechanical implant such as an aneurysm clip, hip replacement, or any other pieces of metal that have accidentally entered their body.",true,{"count":203,"type":23},125,"This study aims to investigate the characteristics of the microbiota-gut-brain axis in pediatric patients with obsessive-compulsive disorder (OCD) through performing an integrated analysis of gut microbiota, serum metabolomics, neuroimaging and electroencephalography (EEG), conducted before and after treatment with selective serotonin reuptake inhibitors (SSRIs). The results will be compared with those of pediatric OCD paitents comorbid with tic disorder (TD) and healthy controls. The findings are expected to further elucidate the potential pathogenesis of OCD, providing a theoretical basis for identifying novel clinical intervention targets and optimizing treatment strategies.",[29,206],"Tic Disorder",[208,209,210],"microbiota-gut-brain axis","pediatric OCD","microbiome","2026-07-30",{"date":186,"type":34},{"date":214,"type":34},"2024-08-24",{"date":216,"type":23},"2027-12-31",{"name":218,"class":41},"Shanghai Mental Health Center",{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":18,"minAge":226,"maxAge":51,"enrollmentInfo":227,"targetDuration":4,"studyType":24,"phases":229,"briefSummary":230,"conditions":231,"keywords":232,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":79},"100648933","phase-2-sonata-lifu-for-ocd-100648933","NCT07728994","SONATA LIFU for OCD","Safety and Feasibility Study of ATTN201 Repeated Subthalamic Nucleus Focused Ultrasound Stimulation for the Treatment of Obsessive Compulsive Disorder","Inclusion Criteria:\n\n1. Have a principal diagnosis of OCD according to the DSM-5 with duration of \\> 1 year\n2. Have a Y-BOCS of \\> 16\n3. Participants currently on OCD medication must be at the same stable dose(s) for at least 3 weeks prior to screening and throughout the course of the study, and must continue to be under the care of their treating psychiatrist through the duration of the study.\n4. Be between 22 to 80 years of age (inclusive) on the day of signing informed consent.\n5. Be able and willing to undergo a cranial MRI\n6. Be able and willing to wear an Attune device throughout the experimental sessions.\n7. Sign the informed consent form, in accordance with local requirements, after the scope and nature of the investigation have been explained to the subject, and before screening assessments.\n8. Be able to speak, read, and understand the language of the trial staff and the informed consent form.\n9. Possess the ability to respond verbally to questions, follow instructions, and complete study assessments.\n10. Be able to adhere to the stimulation protocol and visit schedules.\n11. Be determined by the investigator to be medically stable at baseline\u002Frandomization as assessed by medical history and non-significant clinical results of a vital signs examination.\n12. Male participants must ensure a condom is used for all sexual intercourse and follow acceptable methods of contraception for their female partner for the entire duration of the study. Male participants should not father a child or donate sperm for this same period.\n13. Female participants who are sexually active agree to use two methods of contraception for the duration of the study or not be of childbearing potential as indicated by one of the following:\n\n    1. Has reached natural menopause, defined as 45 years of age with ≥6 months of spontaneous amenorrhea\n    2. Has had a hysterectomy;\n    3. Has had bilateral tubal ligation; or\n    4. Has had a bilateral oophorectomy (with or without a hysterectomy) and greater than 6 weeks have passed since the surgery\n\nExclusion Criteria:\n\n1. Has a current or prior history of bipolar I or II disorder, schizophrenia or other psychotic disorder, borderline personality disorder, Tourette's disorder\n2. Has acute suicidality or suicide attempt or self-injurious behavior in the last 6 months\n3. Has a history of deep brain stimulation or ablative surgery\n4. Has a history of substance abuse including alcohol use disorder in the past 6 months (except for caffeine and nicotine)\n5. Has a history of traumatic brain injury with loss of consciousness, seizures,or other neurological disorders.\n6. Has any contraindications for completing a brain MRI scan.\n\n   a. The subject's head must fit within the head coil (32 or 64 channel), while wearing the MR-compatible device.\n7. Has had a ketamine or TMS treatment within the last month prior to recruitment.\n8. Has had any medical or psychiatric symptoms or conditions that could interfere with study activities or confound interpretation of study results.\n9. Has a recent or ongoing, uncontrolled, clinically significant medical condition where participation in the trial would pose a significant medical risk to the subject or would confound study results within 3 months of Screening, such as:\n\n   1. Conditions including but not limited to diabetes, hypertension, Human Immunodeficiency Virus (HIV) or other relevant infections, thyroid or endocrine disease, Chronic Obstructive Pulmonary Disease (COPD), delirium, congestive heart failure, angina, cardiac or gastrointestinal disease, or renal disease requiring dialysis, or unstable malignancies.\n   2. Major surgery including not limited to abdominal, thoracic, cardiac, or orthopedic surgery, or any procedure requiring general anesthesia.\n   3. Subjects with recently controlled or treated medical conditions may be considered for re-screening on a case-by-case basis after consultation with the Sponsor.\n   4. Has a history of hepatitis or liver disease that, in the opinion of the investigator, has been active within the 6 months prior to Visit 1.\n10. Is pregnant, is attempting to become pregnant, or is nursing children.\n11. Is or has an immediate family member (e.g., spouse, parent\u002Flegal guardian, sibling, or child) who is an investigational site or sponsor staff directly involved with this trial.\n12. Has a Body Mass Index (BMI) \\>34 kg\u002Fm2. BMI is calculated by taking the subject's weight in kg and dividing by the subject's height in meters, squared","22 Years",{"count":228,"type":23},40,[126],"The study tests ATTN201, an investigational non-invasive headband that delivers low-intensity focused ultrasound (LIFU) to the subthalamic nucleus (STN) as a treatment for obsessive-compulsive disorder (OCD). It's a randomized, double-blind, 1:1 (active: sham) study with 40 total participants spanning 12-16 weeks and 14 in-person and remote visits.",[58],[130,233],"LIFU","2026-07-22",{"date":236,"type":34},"2026-07-27",{"date":238,"type":34},"2026-07-01",{"date":240,"type":23},"2028-10-31",{"name":242,"class":41},"University of Pennsylvania",{"id":244,"slug":245,"hasResults":12,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":18,"minAge":87,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":24,"phases":253,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":79},"100619652","phase-1-psilocybin-whole-mushroom-for-the-treatment-of-obsessive-compulsive-disorder-100619652","NCT07347405","Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.","A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.","Mushroom-OCD","Inclusion Criteria:\n\n* Aged 18 years old, and older\n* Have OCD (DSM-5) based on diagnostic interview using the Structured Clinical Interview for DSM-5 Research Version (SCID).\n* At least moderate severity: Yale-Brown Obsessive Compulsive Scale (YBOCS) score ≥16.\n* Failed at least one adequate trial of guideline concordant treatment.\n* Considered safe for independent living\n* Subjects must discontinue use of any of the following prescription or over the counter (OTC) products or nutritional supplements at least two weeks prior to initiating double-blind treatment:\n\n  * Monoamine oxidase (MAOI), UGT1A10, and UGT1A9 inhibitors\n  * Other active OCD treatments (cognitive behavioral therapy \\[CBT\\] or other psychotherapy; electrical or magnetic device treatments; pharmacological treatments such as antidepressant medications (e.g., SSRIs, SNRIs, MAOIs, TCAs, 5HT2 blockers, NERIs, etc.), lithium, antipsychotic drugs, 5-HT2 antagonists such as pimavanserin, and glutamatergic acting medications)\n\n    \\* Note that fluoxetine must be discontinued at least 6 weeks prior to initiating double-blind treatment.\n  * 5HT2 agonists (e.g., efavirenz, lorcaserin), which may alter the response to psilocybin\n  * Serotonin-acting dietary supplements (e.g., 5-hydroxy-tryptophan, St. John's wort) due to potential for interaction with psilocybin and increased safety risks\n\nExclusion Criteria:\n\n* Concurrent active substance use disorder, or a personal history of psychosis.\n* History of psychosis among first degree relatives as determined by the Family Interview for Genetic Studies (FIGS)32\n* Medical illness based on physical examination and routine blood testing that may complicate cardiovascular safety or drug metabolism or excretion. Examples include: 1) Cardiovascular conditions: lifetime history of stroke, lifetime myocardial infarction, uncontrolled hypertension (resting blood pressure \\>140\u002F90 mmHg), tachycardia (resting heart rate \\>100 beats per minute), elongated QT interval corrected by Fridericia's formula (QTcF; interval \\>450 msec), participants with existing valvular heart disease, or clinically significant arrhythmia (\\\u003C1 year prior to signing the ICF); 2) Metabolic conditions: subjects with diabetes should have a stable diabetes treatment regimen and no history of diabetic ketoacidosis, hyperglycemic coma, or no hypoglycemic episodes with glucose below 54 mg\u002FdL in the 3 months prior to baseline, and fasting glucose \\>70 mg\u002FdL at baseline; 3) Severe renal impairment: eGFR \\\u003C45 mL\u002Fmin\u002F1.73 m²); and Liver failure: Child-Pugh Classes B and C.\n* Unstable Chronic Obstructive Pulmonary Disease (COPD) or severe sleep apnea\n* Clinically significant renal or hepatic impairment, per clinical judgment of a study physician\n* EKG QTc ≥ 450 msec\n* Psychiatric comorbidity that may represent an acute risk to their own or other's safety, including history of bipolar disorder (I or II) in the participant or first degree relative, as well as any family history of psychosis.\n* Subjects cannot require any sedative, narcotic, or neuroleptic medications on a regular basis. Any of these medications they have taken should have been stopped long enough in the past to allow for their elimination and safe withdrawal prior to starting administration of the study drug. The specific time required will be dependent on the medication the patient was previously receiving.\n* Participants who are pregnant, breastfeeding, planning a pregnancy, or planning to donate sperm within three months post-last study drug administration.\n* Participants of childbearing potential or participants with partners of childbearing potential who engage in intercourse which could result in pregnancy are unwilling\u002Funable to practice medically acceptable highly effective birth control (double barrier, oral and injectable pharmacological contraceptives, or surgical such as vasectomy or bilateral tubal occlusion) during the study and up to three months after the last study drug administration.\n* Suicide attempt within the 12 months prior to enrollment\n* Any condition for which MRI is contraindicated, at the discretion of a study investigator or the MRI technician, including: Pacemakers and defibrillators; artificial heart valves which are not MRI safe; any metal in head, spinal cord, eyes or chest; any electrical devices such as cochlear implants, nerve stimulators, deep brain stimulators, gastric pacemaker, or insulin or pain pumps; aneurysm clips; ferrous (i.e. non titanium alloy) implants in any part of the body.\n* Use within the week prior to screening of drugs of abuse as listed in the current US DOJ DEA Drugs of Abuse Resource Guide, including:\n\n  * Cannabinoids (marijuana, synthetic cannabinoids)\n  * Simulants (amphetamine, cocaine, methamphetamine, methylphenidate, modafinil)\n  * Opioids (natural and synthetic),\n  * Sedatives (benzodiazepines, barbiturates, GHB, zolpidem, zaleplon, zopiclone)\n  * Hallucinogens (DMT, ibogaine, LSD, MDMA, psilocybin, psilocin, PSP)\n* Weight below 45kg\n* Allergy or significant intolerance to chocolate or cocoa",{"count":252,"type":23},30,[125],"The study tries to improve our treatments for people who have obsessive-compulsive disorder (OCD) by testing psilocybin, a mind altering drug that changes activity in brain areas involved in OCD. 30 patients with moderate or more severe OCD who are not taking mind altering medications or street drugs will participate in a 12 week study. Participants will be assigned (by luck of the draw) to take a low, medium, or high dose whole psilocybin mushroom contained in three chocolate pieces, prepared for this study by the Scottsdale Research Institute.",[29],"2026-07-21",{"date":258,"type":34},"2026-07-23",{"date":260,"type":34},"2026-05-18",{"date":262,"type":23},"2029-01-31",{"name":264,"class":41},"Francisco A Moreno",{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":121,"enrollmentInfo":273,"targetDuration":4,"studyType":24,"phases":275,"briefSummary":276,"conditions":277,"keywords":278,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":290,"locationsCount":42},"100645576","digital-mindfulness-based-therapy-for-obsessive-compulsive-disorder-100645576","NCT07701616","Digital Mindfulness-Based Therapy for Obsessive-Compulsive Disorder","Effects and Neurophysiological Mechanisms of Digital Mindfulness-Based Therapy for Obsessive-Compulsive Disorder","dMBT-OCD","Inclusion Criteria:\n\n1. A primary diagnosis of obsessive-compulsive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).\n2. Aged 12 to 65 years.\n3. Primary school education or above and able to understand the study procedures and complete the required assessments.\n4. Willing and able to provide written informed consent. For participants under 18 years of age, written informed consent will also be obtained from a parent or legal guardian.\n5. Participants who are already receiving psychotropic medication must have maintained a stable medication regimen for at least 4 weeks before enrollment. Any clinically necessary medication changes during the study will be documented.\n\nExclusion Criteria:\n\n1. Current or lifetime diagnosis of schizophrenia spectrum disorder, bipolar disorder, substance use disorder, or personality disorder.\n2. Severe physical illness or central nervous system disease that may interfere with participation in the study.\n3. Severe suicidal ideation or suicidal behavior within the past month.\n4. Pregnancy, planned pregnancy, or breastfeeding.\n5. Concurrent participation in another psychotherapy program or clinical trial.\n6. Mindfulness practice within the past month.\n7. Inability to understand or comply with the study procedures.",{"count":274,"type":23},150,[26],"This randomized controlled trial aims to evaluate the effects of digital mindfulness-based therapy in people with obsessive-compulsive disorder and to explore its possible psychological and neurophysiological mechanisms.\n\nA total of 150 participants with a primary diagnosis of obsessive-compulsive disorder will be randomly assigned in a 1:1:1 ratio to one of three groups: digital mindfulness-based therapy, routine pharmacological treatment, or digital mindfulness-based therapy combined with routine pharmacological treatment.\n\nThe digital mindfulness-based therapy program will last for 6 weeks and will be delivered through a mobile mini-program using structured video and audio lessons, guided mindfulness practices, supervised weekly learning, and home practice. Participants in the pharmacological treatment group will receive routine pharmacological treatment for obsessive-compulsive disorder, and participants in the combined group will receive both interventions.\n\nChanges in obsessive-compulsive symptoms, mindfulness, emotional symptoms, and other psychological outcomes will be assessed during treatment and follow-up. Heart rate variability will be assessed at baseline and weekly during the 6-week intervention. Electroencephalography will be assessed at baseline, at the end of the 6-week intervention, and at the 3-month and 6-month follow-up assessments to explore neurophysiological changes associated with treatment.",[29],[279,280,281,282,283],"Mindfulness","Digital Mindfulness-Based Therapy","Digital Intervention","Electroencephalography","Obsessive-Compulsive Symptoms","2026-07-17",{"date":286,"type":34},"2026-07-20",{"date":288,"type":34},"2026-07-15",{"date":240,"type":23},{"name":291,"class":41},"Central South University",{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":18,"minAge":87,"maxAge":121,"enrollmentInfo":300,"targetDuration":4,"studyType":24,"phases":302,"briefSummary":303,"conditions":304,"keywords":311,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":42},"100545041","phase-2-search-for-novel-transcranial-magnetic-stimulation-tms-targets-for-mental-illness-100545041","NCT06376734","Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness","Transdiagnostic Circuit Mapping of Prefrontal Targets in Accelerated Transcranial Magnetic Stimulation","Expedition","Inclusion Criteria:\n\n* Age 18-65\n* English proficiency sufficient for informed consent, questionnaires\u002Ftasks, and treatment\n* Primary diagnosis of one of the following: major depressive disorder (MDD), obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), or schizophrenia (determined by focal assessment using the Structured Clinical Interview for DSM-5)\n\n  * ≥20 on the Beck Depression Inventory for patients with MDD\n  * ≥16 on the Beck Anxiety Inventory for patients with GAD\n  * ≥16 on the Yale-Brown Obsessive-Compulsive Scale for patients with OCD\n  * ≥58 on the Positive and Negative Symptom Scale for patients with schizophrenia\n* Stable psychotropic medication regimen, or remain medication free, for 4 weeks prior to treatment (Medication changes during study enrollment period will be tracked for post hoc analysis).\n* Primary clinician (e.g. psychiatrist, therapist, psychologist, APRN, PA, etc.) responsible for psychiatric care before, during, and after the trial\n\nExclusion Criteria:\n\n* Active pregnancy as determined by a urine pregnancy test\n* Cluster B personality disorders (antisocial personality disorder, borderline personality disorder, histrionic personality disorder, narcissistic personality disorder)\n* PTSD with active, clinically significant symptoms, as determined by clinician\n* Diagnosis of Schizoaffective Disorder, Bipolar Type\n* Recent (within 4 weeks) or concurrent use of rapid-acting antidepressant agent (ketamine\u002Fesketamine\u002FECT)\n* Ferromagnetic metallic implant that would contraindicate receiving TMS or obtaining MRI\n* Any other TMS or MRI safety concerns identified by the clinician\n* Receiving or planning to receive other TMS treatments during course of participation\n* History of:\n\n  * Neurosurgical intervention for mental illness\n  * Moderate to severe autism spectrum disorder\n  * Intellectual disability\n  * Severe cognitive impairment\n  * Significant neurological illness (e.g., dementia, Parkinson's, Huntington's, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis)\n  * Untreated or insufficiently treated endocrine disorder\n  * Eating disorders\n  * Treatment with investigational drug or intervention during the study period\n* Current evidence of:\n\n  * Mania or hypomania\n  * Active suicidal ideation or a suicide attempt within the past year\n  * Contraindications to either TMS or MRI (e.g., metallic implants, etc.).\n  * Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal\n  * Significantly increased seizure risk as determined by a clinician\n* For participants with schizophrenia:\n\n  * Evidence of impaired capacity to consent, e.g. impaired insight into illness, as deemed by a licensed psychiatrist or psychologist on the study team\n  * Hospitalization with psychosis in the past 6 months\n* Positive urine drug screen for illicit substances\n* Existing tinnitus (ringing in the ears)\n* Any other condition deemed by the PI to interfere with the study or increase risk to the participant",{"count":301,"type":23},180,[126],"Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.",[305,29,306,99,307,308,309,310],"Major Depressive Disorder","Schizophrenia","Mood Disorders","Psychiatric Disorder","Mental Disorder","Depression, Anxiety",[312,102,313,130,314,315,316,317,318,319,320,321,322,323,324,325],"depression","schizophrenia","obsessive-compulsive disorder","transcranial magnetic stimulation","TMS","accelerated TMS","accelerated intermittent theta burst stimulation","brain stimulation","neuromodulation","transdiagnostic","neuronavigation","functional connectivity","neuroimaging","theta burst stimulation","2026-07-14",{"date":328,"type":34},"2026-07-16",{"date":330,"type":34},"2025-01-30",{"date":332,"type":23},"2030-06-01",{"name":334,"class":41},"Brigham and Women's Hospital",{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":18,"minAge":87,"maxAge":342,"enrollmentInfo":343,"targetDuration":4,"studyType":24,"phases":345,"briefSummary":346,"conditions":347,"keywords":349,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":79},"100647237","safety-and-feasibility-of-fus-next-generation-dome-helmet-ngdh-to-perform-neuromodulation-in-patients-with-treatment-refractory-obsessive-compulsive-disorder-ocd-100647237","NCT07704632","Safety and Feasibility of FUS Next Generation Dome Helmet (NGDH) to Perform Neuromodulation in Patients With Treatment Refractory Obsessive Compulsive Disorder (OCD)","Assessment of Safety and Feasibility of FUS Next Generation Dome Helmet (NGDH) to Perform Neuromodulation in Patients With Treatment Refractory Obsessive Compulsive Disorder (OCD)","Inclusion Criteria:\n\n1. Must be deemed to have the capacity to provide informed consent.\n2. Age 18 to 85 years.\n3. Diagnosis of obsessive-compulsive disorder according to DSM-5 criteria.\n4. Yale-Brown Obsessive Compulsive Scale total score greater than 22.\n5. If taking psychiatric medications, must be on a stable regimen for at least 30 days before enrollment. Psychiatric medications will be continued throughout the study.\n6. Previous trial of at least two first-line antidepressant agents at an adequate dose and duration, as assessed by two psychiatrists.\n7. Previous trial of cognitive behavioural therapy or psychotherapy for OCD for at least 6 weeks.\n\nExclusion Criteria:\n\n1. Pregnant or intending to become pregnant during the study.\n2. Substance use disorder, other than cannabis or nicotine use disorder, of moderate severity or greater, or where the substance is the primary substance of concern, according to DSM-5 criteria.\n3. Known active seizure disorder or significant head injury with an imaging-confirmed lesion.\n4. Unstable medical illness.\n5. Not eligible for 3-Tesla MRI, such as due to an MRI-incompatible pacemaker or other implanted device.\n6. Unable to reliably attend the required screening, treatment, and follow-up visits.\n7. Severe claustrophobia that would prevent MRI scanning.\n8. History of a bleeding disorder or coagulopathy.\n9. Anticoagulant therapy or use of medications known to increase the risk of hemorrhage within the required washout period before treatment, including:\n\n   * Antiplatelet agents or vitamin K antagonist anticoagulants within 7 days of treatment\n   * Non-vitamin K oral anticoagulants within 72 hours of treatment\n   * Heparin-derived compounds within 48 hours of treatment","85 Years",{"count":344,"type":23},20,[26],"This study evaluates the safety, feasibility, and preliminary efficacy of focused ultrasound (FUS) neuromodulation delivered using the Next Generation Dome Helmet (NGDH) in participants with treatment-refractory obsessive-compulsive disorder (OCD). Participants will undergo two study sessions, four weeks apart, involving active FUS neuromodulation targeting nodes of the cortico-striato-thalamo-cortical (CTSC) circuit. Outcomes include adverse events, changes in OCD symptom severity, and quality of life.",[130,348,29],"Obsessive-Compulsive Disorder (OCD)",[350,351,352],"Focused ultrasound (FUS)","MRgFUS","FUS Neuromodulation","2026-07-10",{"date":288,"type":34},{"date":356,"type":34},"2025-09-23",{"date":358,"type":23},"2027-09",{"name":360,"class":41},"Sunnybrook Health Sciences Centre",{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":18,"minAge":87,"maxAge":121,"enrollmentInfo":368,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":369,"conditions":370,"keywords":371,"overallStatus":372,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":381},"100309842","locating-biomarkers-in-ocd-through-behavioral-tasks-100309842","NCT03313622","Locating Biomarkers in OCD Through Behavioral Tasks","Locating Biomarkers of Medically Intractable Obsessive Compulsive Disorder (OCD) Through the Use of Behavioral Tasks","Inclusion Criteria:\n\n* Diagnosis of OCD\n* Non-pregnant if female\n* Minimum score of 16 on Y-BOCS\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Those not meeting inclusion criteria listed above\n* Lifetime diagnosis of psychotic disorders such as schizophrenia\n* Alcohol or substance abuse\u002Fdependence within 6 months, excluding nicotine\n* Deemed at high risk of suicidal behavior or impulsivity\n* Pregnant or plans to become pregnant in the next 24 months",{"count":344,"type":23},"Subjects that have a diagnosis of OCD will participate in a clinical interview and cognitive tasks, during which they will be exposed to their individual OC stressors or will be asked to make decisions related to information value and quantity while measuring neural activity and filming facial reactions. This will assist investigators to look for biomarkers of that change. This study offers a unique opportunity to develop biomarkers for key domains of OCD, and other neuropsychiatric disorders, that are grounded in brain neurocircuitry at the individual-patient level.\n\nSubjects will participate in a clinical interview (Day 1), and then tasks+EEG (Day 2). Day 1 will be 4 hours or less, and Day 2 will be 2.5 hours or less.",[130,29],[130,58],"NOT_YET_RECRUITING","2026-06-26",{"date":375,"type":34},"2026-06-30",{"date":377,"type":23},"2027-03",{"date":379,"type":23},"2028-03",{"name":194,"class":41},3,{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":18,"minAge":87,"maxAge":121,"enrollmentInfo":389,"targetDuration":4,"studyType":24,"phases":391,"briefSummary":392,"conditions":393,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":42},"100529436","mechanisms-of-exposure-therapy-for-ocd-100529436","NCT06173752","Mechanisms of Exposure Therapy for OCD","Leveraging Machine Learning Approaches to Understand Mechanisms of Exposure Therapy in Real-World Settings","Inclusion Criteria:\n\n* Between the ages of 18-65 years old\n* Seeking exposure treatment at McLean Hospital OCD Institute or San Diego State University\n* Have a diagnosis of OCD\n* Able to complete study measures and treatment procedures in English\n\nExclusion Criteria:\n\n* Acute symptoms of psychosis\n* Active suicidality (plan, means, intent and\u002For suicide attempt in past 3 months)\n* Presence of co-occurring symptoms that warrant higher level of care (e.g., inpatient treatment)\n* Presence of any medical, psychiatric, or developmental condition that would prevent patients from completing assessments or exposure exercises (e.g., non-verbal autism spectrum disorder)",{"count":390,"type":23},400,[26],"Exposure therapy is the most effective treatment available for obsessive compulsive disorder, yet up to 50% of patients do not recover because the mechanisms underlying successful response are poorly understood, leading to significant variability in how clinicians conduct exposure therapy. The main purpose of this study is to determine which target mechanisms are most critical to engage in real-world exposure sessions to produce good treatment outcomes. Adult participants (N = 400) with Obsessive Compulsive Disorder (OCD) receiving exposure therapy from two sites (McLean Hospital, San Diego State University) across the continuum of care (outpatient, partial hospital, residential) will complete baseline clinical and demographic measures as well as weekly symptom reports. The project will measure exposure mechanisms across three levels of analysis (self-report, observer-rated behavior, physiology) during each exposure session. Mechanisms assessed will include a broad range of variables based on both habituation and inhibitory learning models of exposure. Self-report and observer-rated mechanisms will be measured with the Exposure Feedback Form, created and piloted by the study team. Physiological mechanisms will include skin conductance response, heart rate, and heart rate variability measured with a wristwatch. The current study will determine (1) which exposure mechanisms lead to favorable clinical outcomes, and (2) what makes a good exposure for whom. Results of this study have the potential to improve personalized care for the many patients who do not remit following exposure therapy for OCD.",[29],"2026-06-24",{"date":396,"type":34},"2026-06-25",{"date":398,"type":34},"2024-10-16",{"date":400,"type":23},"2029-04",{"name":402,"class":41},"Mclean Hospital",{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":201,"sex":18,"minAge":87,"maxAge":4,"enrollmentInfo":410,"targetDuration":4,"studyType":24,"phases":412,"briefSummary":413,"conditions":414,"keywords":415,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":79},"100605152","project-empower-ocd-100605152","NCT07158801","Project EMPOWER-OCD","A Web-based Single Session Intervention to Reduce Caregiver Distress and Accommodation in Socioeconomically Diverse Caregivers of OCD Patients","Inclusion Criteria:\n\n* be a caregiver for at least one individual with OCD, defined as living in the same household and providing daily care\n* be 18 years old or older\n* the individual they are caring for have clinically significant OCD symptoms, indicated by a score a 16 or above on the self-reported Children's Yale-Brown Obsessive Compulsive Scale - Parent Report (CY-BOCS-PR)\n* speak, read, and write English\n* not be in concurrent family-based CBT treatment for the patient's OCD.\n\nExclusion Criteria:\n\n* does not speak English\n* younger than 18 years old\n* participation in concurrent family-based CBT treatment for the patient's OCD.",{"count":411,"type":23},110,[26],"This research study aims to adapt and evaluate the acceptability and effectiveness of Project EMPOWER-OCD for socioeconomically diverse caregivers of patients with OCD. Designed to reduce obstacles (e.g. months long time commitment, high cost, transportation) to treatment that caregivers may be particularly prone to, project EMPOWER-OCD will provide targeted intervention of accommodation - a well-established, potentially modifiable risk factor for child anxiety, OCD, and its related disorders - in a single, self-guided session via an online format.",[29],[416,29,417,418],"Parental Accommodation","Caregiving","Single Session Interventions","2026-06-08",{"date":421,"type":34},"2026-06-10",{"date":423,"type":34},"2025-03-25",{"date":425,"type":23},"2026-09",{"name":427,"class":41},"Boston University Charles River Campus",{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":18,"minAge":87,"maxAge":121,"enrollmentInfo":435,"targetDuration":4,"studyType":24,"phases":436,"briefSummary":437,"conditions":438,"keywords":439,"overallStatus":372,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":440,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":4},"100601553","phase-2-valbenazine-in-obsessive-compulsive-disorder-100601553","NCT07111988","Valbenazine in Obsessive Compulsive Disorder","Valbenazine in Obsessive-compulsive Disorder: A Randomized Double-blind Placebo-controlled Crossover Trial","Inclusion Criteria:\n\n1. Men and women aged 18-65 years\n2. Primary diagnosis of obsessive compulsive disorder (OCD)\n3. Yale Brown Obsessive Compulsive Scale (Y-BOCS) score of at least 21 at baseline (moderate or higher severity)\n4. Ability to understand and sign the consent form\n\nExclusion Criteria:\n\n1. Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination\n2. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential\n3. Subjects considered an immediate suicide risk based on the Columbia Suicide Severity Rating Scale (C-SSRS) (www.cssrs.columbia.edu\u002Fdocs)\n4. History of psychosis or bipolar disorder based on DSM-5 criteria\n5. Alcohol\u002Fsubstance use disorder and\u002For illegal substance use based on urine toxicology\n6. Initiation of psychological interventions within 3 months of screening (those who are continuing with CBT will be included)\n7. Use of any new psychotropic medication within 3 months of study entry (stable doses of psychotropics will be allowed)\n8. Major cognitive impairment that interferes with the capacity to understand and self-administer medication or provide written informed consent\n9. Abnormal liver function tests at baseline (greater than 2x the upper limit of normal)",{"count":252,"type":23},[126],"The primary aim of the study is to examine the efficacy and safety of valbenazine in adults with moderate to severe obsessive-compulsive disorder (OCD).",[29],[130],{"date":421,"type":34},{"date":442,"type":23},"2026-06",{"date":444,"type":23},"2027-12",{"name":446,"class":41},"University of Chicago",{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":18,"minAge":87,"maxAge":454,"enrollmentInfo":455,"targetDuration":4,"studyType":24,"phases":456,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":461,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":42},"100475189","co2-reactivity-as-a-biomarker-of-non-response-to-exposure-based-therapy-100475189","NCT05467683","CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy","Carbon Dioxide (CO2) Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy","Inclusion Criteria:\n\n* A primary DSM-5 diagnosis of panic disorder (with or without an agoraphobia diagnosis), social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, or post-traumatic stress disorder as assessed by the Structured Clinical Interview for the DSM-5 (SCID-5)\n* A score of 8 or greater on the Overall Anxiety Severity and Impairment Scale (OASIS)\n* Ages 18 to 70\n* Willingness and ability to provide informed consent and comply with the requirements of the study protocol.\n* Proficiency in English (because assessment instruments have only been validated in English)\n\nExclusion Criteria:\n\n* A lifetime history of bipolar or psychotic disorders, substance use disorders (other than nicotine) or eating disorder in the past 6 months; serious cognitive impairment.\n* Active suicidal ideation with at least some intent to act with or without specific plan (a rating of 4 for suicidal ideation on the Columbia-Suicide Severity Rating Scale) or suicidal behaviors (actual attempt, interrupted attempt, aborted or self-interrupted attempt, or preparatory acts or behavior) within the past 6 months.\n* Medical conditions contraindicating CO2 inhalation or hyperventilation challenge (e.g., cardiac arrhythmia, cardiac failure, asthma, lung fibrosis, high blood pressure, epilepsy, or stroke).\n* Pregnancy or lactation\n* Ongoing psychotherapy directed toward the primary disorder.\n* Pharmacological treatment started within 8 weeks prior to the screen (patients \"stable\" on their medication regimen will be included and their medication status will be included as a variable in the model)","70 Years",{"count":89,"type":23},[26],"Anxiety-, obsessive-compulsive and trauma- and stressor-related disorders reflect a significant public health problem. This study is designed to evaluate the predictive power of a novel biomarker based on a CO2 challenge, thus addressing the central question \"can this easy-to-administer assay aid clinicians in deciding whether or not to initiate exposure-based therapy?\"",[29,459,99,97,460],"Post Traumatic Stress Disorder","Panic Disorder",{"date":421,"type":34},{"date":463,"type":34},"2022-11-02",{"date":465,"type":23},"2027-02-28",{"name":467,"class":41},"Jasper A. Smits",{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":18,"minAge":87,"maxAge":121,"enrollmentInfo":475,"targetDuration":4,"studyType":24,"phases":476,"briefSummary":477,"conditions":478,"keywords":482,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":79},"100431561","phase-2-study-of-dextromethorphan-in-ocd-and-related-disorders-100431561","NCT04899687","Study of Dextromethorphan in OCD and Related Disorders","Fluoxetine\u002FDextromethorphan in Obsessive-Compulsive and Related Disorders: an Open-Label Crossover Pilot Study","Inclusion Criteria:\n\n* Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD)\n* Living within California\n* Capacity to provide informed consent\n\nExclusion Criteria:\n\n* Current bipolar disorder or psychotic disorder\n* Active moderate or severe substance use disorder, lifetime severe substance use disorder\n* Pregnant or nursing women\n* Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start\n* Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start",{"count":22,"type":23},[126],"The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.",[29,479,480,481],"Illness Anxiety Disorder","Body Dysmorphic Disorders","Somatic Symptom Disorder",[130,483,484,485,486,487],"BDD","IAD","SSD","Fluoxetine","Dextromethorphan",{"date":489,"type":34},"2026-05-20",{"date":491,"type":34},"2022-01-20",{"date":493,"type":23},"2028-12-01",{"name":495,"class":41},"Stanford University",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":18,"minAge":87,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":24,"phases":504,"briefSummary":505,"conditions":506,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":79},"100456501","interpretation-bias-as-a-mechanism-of-treatment-response-in-ocd-100456501","NCT05224414","Interpretation Bias as a Mechanism of Treatment Response in OCD","Inclusion Criteria:\n\n* 1\\) OCD Institute patients\n* 2\\) adults (\\> 18 years old)\n* 3\\) able to complete a computer task for 20 minutes\n* 4\\) consent to main OCD Institute study protocol\n* 5\\) primary diagnosis of OCD (as measured by a score of \\>16 on the Y-BOCS and a clinical diagnosis of OCD by their treatment team\n* 6\\) score of \\>131 on the Obsessive Beliefs Questionnaire-44 at admission \\[which is 1 SD above the mean score of the non-clinical sample reported in the original validation paper by the Obsessive Compulsive Cognitions Working Group (2005)\\]\n\nExclusion Criteria:\n\n* 1\\) Currently experiencing acute symptoms of psychosis\n* 2\\) Psychotic disorder diagnosis",{"count":503,"type":23},106,[26],"This study will conduct a randomized controlled trial of Cognitive Bias Modification for Interpretation (CBM-I) as an augmentation to treatment as usual for obsessive compulsive disorder (OCD). CBM-I is a digital intervention designed to directly manipulate interpretation bias through repeated practice on a training task, thereby inducing cognitive changes in a relatively automatic or implicit manner. Specifically, this study will examine the feasibility, acceptability, and clinical outcomes associated with CBM-I.\n\nAdults with obsessive compulsive disorder (OCD) will be recruited from a treatment program for this disorder and participants will be randomly assigned to either receive: 1) up to 12 sessions of CBM-I, or or up to 12 sessions of psychoeducation as a control condition.",[29],"2026-05-15",{"date":260,"type":34},{"date":510,"type":34},"2022-03-30",{"date":512,"type":23},"2026-08-31",{"name":402,"class":41},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":520,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":18,"minAge":226,"maxAge":522,"enrollmentInfo":523,"targetDuration":4,"studyType":24,"phases":525,"briefSummary":526,"conditions":527,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":42},"100487148","seeg-guided-dbs-for-ocd-100487148","NCT05623306","SEEG-Guided DBS for OCD","A Double-Blinded, Randomized, Crossover Trial of Stereoencephalography- Guided Multi-Lead Deep Brain Stimulation for Treatment-Refractory Obsessive-Compulsive Disorder (SEEG-Guided DBS for OCD)","SEEG-DBS-OCD","Inclusion Criteria:\n\n1. ≥ 22 years and ≤ 75 years of age, at the time of screening\n2. Chronic (\\> five years preceding the date of enrollment) OCD, diagnosed as per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition guidelines (DSM-5)\n\n   1. Presence of obsessions, compulsions, or both\n   2. Time-consuming obsessions and compulsions that take more than one hour a day or cause clinically significant distress or impairment in social, occupational, or other important areas of functioning\n   3. Obsessive-compulsive symptoms that are not attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication) or another medical condition\n   4. Disturbance not better explained by the symptoms of another mental disorder listed in the DSM-5\n3. Severe OCD symptoms, as defined by Y-BOCS I score of ≥ 28, within two weeks prior to enrollment\n4. Lack of adequate response to a history of the following treatments, based on information from any of the following: (a) the current treating physician and\u002For psychologist; (b) medical records or other forms of communication from previous healthcare providers; and (c) pharmacy records, as determined by the PI\n\n   1. Adequate trial of ≥ 2 selective serotonin reuptake inhibitors (SSRIs) for an adequate duration at the maximum dose recommended for OCD or at the maximally- tolerated dose according to the FDA-approved package labeling\n   2. Adequate trial of ≥ 1 augmentation trial using an antipsychotic medication\n   3. Adequate trial of clomipramine, either as monotherapy or as an augmentation therapy, unless medically contradicted\n   4. Adequate trials of cognitive behavior therapy-based Exposure and Response Prevention (ERP)\n5. Willingness and ability to remain on the same daily dose of any and all scheduled psychotropic medication(s) for at least eight weeks prior to study enrollment and for the duration of the trial, as determined by the research\u002Fstudy psychiatrist and the PI\n6. Willingness and ability to discontinue or refrain from initiating ERP therapy until the maintenance stage, if any, as determined safe by the research\u002Fstudy psychiatrist\n7. Study participation in the prospective subject's best psychiatric interest, as determined by the research\u002Fstudy psychiatrist and based on a comprehensive assessment that includes the following: (a) detailed psychiatric history; (b) examination of the mental status; (c) review of psychiatric assessment measures obtained to determine eligibility, as applicable; (d) review of previous medical records for a minimum of two years prior to enrollment, or as applicable; and (e) consideration of the potential benefits versus risks of study participation\n8. Agreement to being evaluated by a licensed psychiatrist and\u002For psychologist at regular intervals, as required by the schedule of events, for the duration of study participation\n9. Living within six hours of driving distance from study sites and no plan of relocation for at least the duration of the trial (approximately 18-24 months), as reported by the prospective subject or a family member\n10. Adequate social support, including but not limited to, stable housing and two family members and\u002For friends, who are identified as verifiable emergency contacts\n11. Willingness and ability to provide at least two verifiable contacts for emergency purposes and to permit verification of emergency contacts by research staff before all study visits and as needed, at the discretion of the PI\n12. Ability to understand procedure-related instructions and to complete study assessments in English, in the opinion of the PI\n13. Willingness and ability to comply with protocol requirements (e.g., procedure visits, treatment schedule, follow-up visit schedule, evaluations, etc.), in the opinion of the PI\n14. Willingness and ability to provide written agreement to allow any and all forms of communication between the research team and treating clinician(s)\n15. Willingness and ability to provide informed consent, in the opinion of the PI\n\nExclusion Criteria:\n\n1. Diagnosis of, according to the Mini International Neuropsychiatric Interview (MINI), any other primary psychiatric diagnosis defined in the DSM-5, including Hoarding Disorder.\n\n   a. Subjects with secondary psychiatric diagnosis will not be excluded, except as described below.\n2. In the opinion of the PI and relative to the date of enrollment, (a) current or past diagnosis of, or medical history\u002Frecords suggestive of, a DSM-5 defined Personality Disorder, considered to be severe; or (b) history of hospitalization because of Borderline Personality Disorder\n3. Clinical secondary diagnosis made by a psychiatrist, as defined in the DSM-5 and based on the MINI and the psychiatric evaluation:\n\n   a. Lifetime diagnosis of Bipolar I Disorder or Bipolar II Disorder b. Current\u002Factive diagnosis of Anorexia Nervosa, Bulimia Nervosa, or Binge Eating Disorder i. Diagnosis will be considered current\u002Factive if the subject had an active episode within five years of screening.\n\n   c. Lifetime diagnosis of a primary psychotic disorder (e.g. Schizophrenia, Schizoaffective Disorder) d. Current\u002Factive diagnosis of mood disorder with psychotic features i. Diagnosis will be considered current\u002Factive if the subject had an active episode within two years of screening.\n4. Acute suicide risk considered significant by any of the following criteria:\n\n   1. High suicide risk, as determined by the Columbia Suicide Severity Rating Scale (C-SSRS) along with clinician assessment; or\n   2. A suicide attempt within the past twelve months that led to hospitalization; or\n   3. Suicide risk that, in the investigator's clinical judgment, necessitates inpatient treatment based on the individual's history and current condition.\n5. Treatment, within two years of screening, for any of the following: dependency on, addiction to, use of, abuse of, or overuse of any illicit substance(s), including alcohol, but not including nicotine or caffeine\n6. History of head trauma associated with any of the following:\n\n   1. Loss of consciousness for \\> five minutes\n   2. A residual effect(s) that failed to resolve completely at least one year prior to the date of screening\n   3. An abnormality on a neuroimaging study (MRI, CT Scan) that was\u002Fis attributable to the head trauma\n   4. \\> 1 head injury within the past two years which were diagnosed as a concussion, concussive-type or traumatic brain injury (TBI), according to medical records or as reported by the prospective subject or a family member\n7. Any of the following permanent implants:\n\n   1. Cardiac implant (e.g. pacemaker or any intracardiac lines, implanted neurostimulators, shunts)\n   2. Brain implant (e.g. intracranial implant, aneurysm clips, shunts, stimulators, cochlear implants, or electrodes)\n   3. Implanted medical pumps\n8. Diathermy treatments requirement for any reason\n9. Hearing loss that, in the opinion of the PI, an audiologist, or a treating physician, is likely to affect the subject's ability to comply with all of the requirements of the study or may affect the integrity of the study data\n10. Any metal or metallic particles anywhere in the head, except in the inside of the mouth\n11. Pregnancy, at the time of screening or during the course of the study (i.e. three years)\n\n    a. Acceptable methods of contraception include the following: i. Established use of oral, injected or implanted contraceptives ii. Placement of an intrauterine device (IUD) or an intrauterine system (IUS) iii. Female sterilization (e.g. surgical bilateral oophorectomy with or without hysterectomy, total hysterectomy, tubal ligation) iv. Male sterilization, with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate v. True abstinence, when in line with the preferred and usual lifestyle of the subject b. Barrier methods of contraception, such as a condom, a diaphragm, or cervical\u002Fvault caps with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository, and rhythm methods of contraception, although encouraged, alone are not considered acceptable forms or contraception.\n12. History of involuntary movements, in the opinion of the PI or a neuro-radiologist\n13. History of excessive or prolonged bleeding and\u002For any of the following:\n\n    1. INR of \\> 1.8\n    2. Prolonged activated partial thromboplastin time (aPTT) of ≥ 45 sec\n    3. Platelet count of \\\u003C 100×100\u002FL\n14. Allergy to gadolinium\n15. Inability to safely and successfully undergo an MRI or a CT Scan\n16. Any past or present medical condition, disease, disorder, or injury that, in the opinion of the PI, may reduce or hinder the subject's ability to fully comply with all study requirements for the duration of the study or may impact, compromise, or affect the integrity of the data or the results of the study\n17. Current participation in other research that may potentially interfere with DBS study objectives or with the ability to follow the timeline of this study, as determined by the PI.","75 Years",{"count":524,"type":23},12,[26],"This is a multi-site, double-blinded, randomized, crossover study design for SEEG-guided 4-lead DBS for treatment-refractory OCD, followed by open-label stimulation for an additional 6 months. The study will be conducted in 3 stages: Stage 1 will consist of SEEG brain mapping and optimization of stimulation parameters. Stage 2 will consist of DBS surgery and further optimization of stimulation parameters. Stage 3 will be randomized, crossover treatment, followed by open-label treatment.",[29],"2026-05-11",{"date":530,"type":34},"2026-05-14",{"date":532,"type":34},"2023-04-13",{"date":534,"type":23},"2030-04-01",{"name":536,"class":41},"Casey H. Halpern, M.D.",{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":177,"enrollmentInfo":545,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":547,"conditions":548,"keywords":551,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":556,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":79},"100358895","pharmacogenetics-of-antidepressant-induced-disinhibition-100358895","NCT03953014","Pharmacogenetics of Antidepressant-Induced Disinhibition","Pharmacogenetics of Antidepressant-Induced Disinhibition in Children Study","PGx-AID","Inclusion Criteria:\n\n1. Aged 6 - 24 years\n2. Medical records available\n3. Diagnosis of MDD, anxiety disorder, or OCD\n4. Current or past history of SSRI therapy\n\nExclusion Criteria:\n\n1. Inability of parent\u002Flegal guardian to give informed consent\n2. Inability of the child to give informed assent\n3. Unwillingness of child to provide saliva sample for genetic analysis\n4. Current, past or suspected diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, or pervasive developmental disorder.",{"count":546,"type":23},120,"The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and\u002For obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.",[29,549,305,550],"Anxiety Disorders","Antidepressant Drug Adverse Reaction",[552,553,554,130,93,555],"SSRI","Depression","Children","Antidepressants",{"date":530,"type":34},{"date":558,"type":34},"2019-01-02",{"date":560,"type":23},"2026-12-30",{"name":562,"class":41},"University of Calgary",{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":18,"minAge":87,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":24,"phases":571,"briefSummary":572,"conditions":573,"keywords":578,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":79},"100489298","a-precision-medicine-approach-to-target-engagement-for-emotion-regulation-100489298","NCT05651295","A Precision Medicine Approach to Target Engagement for Emotion Regulation","Inclusion Criteria:\n\n* Elevated emotion dysregulation\n\nExclusion Criteria:\n\n* Lack of proficiency in English\n* No access to smartphone\n* Conditions requiring greater than outpatient care",{"count":570,"type":23},390,[26],"The proposed study is designed to first test whether teaching people personalized or standardized emotion regulation skills leads to greater decreases in daily negative emotion intensity. Second, using data from an initial sample, the investigators will prospectively assign an independent sample of participants to receive their predicted optimal or non-optimal skills to determine if it is feasible and efficacious to match participants to the most appropriate training condition. Results of these studies may identify the mechanisms by which emotion regulation interventions impact emotional functioning and allow for the development of personalized, evidence-based, and scalable emotion regulation interventions.",[574,553,93,575,29,576,577],"Emotional Regulation","Borderline Personality Disorder","Posttraumatic Stress Disorder","Eating Disorders",[579,580,581,582],"cognitive-behavior therapy","mechanism","ecological momentary assessment","personalization","2026-05-07",{"date":528,"type":34},{"date":586,"type":34},"2023-09-29",{"date":588,"type":23},"2026-12-31",{"name":590,"class":41},"Matthew Southward, PhD",{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":4,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":18,"minAge":176,"maxAge":177,"enrollmentInfo":598,"targetDuration":4,"studyType":24,"phases":600,"briefSummary":601,"conditions":602,"keywords":603,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":615,"locationsCount":381},"100560828","icbt-for-ocd-in-children-with-autism-100560828","NCT06582225","ICBT for OCD in Children With Autism","Internet-delivered Cognitive-behaviour Therapy for Obsessive- Compulsive Disorder in Children With Autism: A Randomised Controlled Trial","Inclusion Criteria:\n\n1. A diagnosis of autism, based on the diagnostic criteria of the 4th or 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM) or the 10th edition of the International Classification of Diseases (ICD-10). Informed by the parent\u002Fcaregiver and subsequently confirmed by review of the medical record or the neurodevelopmental assessment report. A diagnosis of autism will be considered present if it was established with validated instruments, such as the Autism Diagnostic Interview-Revised (ADI-R), the Autism Diagnostic Observation Schedule (ADOS) edition 1 or 2 or the Diagnostic Interview for Social and Communication Disorders (DISCO; autism or ASD cut-offs).\n2. A DSM-5 diagnosis of OCD. Confirmed by the assessor at the inclusion assessment, based on a structured diagnostic interview.\n3. A total score of ≥16 on the CY-BOCS. Confirmed by the assessor at the inclusion assessment.\n4. Age between 7 and 17 years. Confirmed by the caregiver and subsequently by the medical record system.\n5. Ability to read and write Swedish. Confirmed by the caregiver at the telephone screening or\u002Fand the inclusion assessment.\n6. Regular access to a computer or a smartphone\u002Ftablet connected to the internet, and a mobile phone to receive text messages. Confirmed by the caregiver at the telephone screening or\u002Fand inclusion assessment.\n7. A parent\u002Fcaregiver able to participate in the treatment alongside their child. Confirmed by the caregiver at the telephone screening or\u002Fand the inclusion assessment.\n\nExclusion Criteria:\n\n1. Global intellectual disability. Informed by the parent\u002Fcaregiver and subsequently confirmed by review of the medical record or the neurodevelopmental assessment report, and additionally estimated with the two subtests matrix reasoning and similarities from the Wechsler Intelligence Scale for Children - fifth edition (WISC-V) or Wechsler Adult Intelligence Scale - fourth edition (WAIS-IV).\n2. Comorbid psychotic disorder, bipolar disorder, severe eating disorder, severe depression, alcohol\u002Fsubstance dependence or hoarding disorder. Confirmed by the caregiver at the telephone screening and subsequently by the assessor at the inclusion assessment based on the structured diagnostic interview and, if required, the medical record.\n3. Current suicidal intent or a previous suicide attempt within the last 12 months. Confirmed by the assessor at the inclusion assessment and, if required, the medical record.\n4. Main symptom presentation consists of hoarding symptoms. Confirmed by the assessor at the inclusion assessment.\n5. Completed CBT for OCD within the last 12 months prior to the inclusion assessment (defined as at least 5 sessions of CBT including ERP). Confirmed by the caregiver at the telephone screening or\u002Fand inclusion assessment and, if required, the medical record.\n6. Simultaneous psychological treatment for OCD or anxiety. Confirmed by the caregiver at the telephone screening and\u002For inclusion assessment.\n7. Initiation, dosage change or cessation of medication for OCD (primarily selective serotonin reuptake inhibitors, SSRIs) or behavioural symptoms of ASD (atypical antipsychotics) within the 6 weeks prior to the baseline assessment. Confirmed by the caregiver at the telephone screening and the inclusion assessment and, if required, the medical record.\n8. Having a close relationship to an already included participant (e.g., sibling, cousin), to avoid being randomised into two different arms, with the risk of information \"leaking\" between the groups. Confirmed by the caregiver or assessor at the telephone screening and\u002For at the inclusion assessment.",{"count":599,"type":23},220,[26],"The purpose of this trial is to evaluate the clinical efficacy, the cost-effectiveness and the effect durability of a therapist-guided, internet-delivered cognitive-behavior therapy intervention for obsessive-compulsive disorder (OCD) in children and adolescents with autism. A process evaluation of the treatment will also be conducted.",[29,61],[29,61,604,605,606,607,608],"Exposure and Response Prevention","Cognitive-Behavioural Treatment","Internet","Guided self-help","Stress Management","2026-05-05",{"date":611,"type":34},"2026-05-08",{"date":613,"type":34},"2024-11-25",{"date":444,"type":23},{"name":616,"class":41},"Karolinska Institutet",{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":4,"eligibilityCriteria":623,"healthyVolunteers":12,"sex":18,"minAge":226,"maxAge":522,"enrollmentInfo":624,"targetDuration":4,"studyType":24,"phases":626,"briefSummary":627,"conditions":628,"keywords":629,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":635,"completionDateStruct":636,"leadSponsor":638,"locationsCount":79},"100566826","deep-brain-stimulation-for-refractory-obsessive-compulsive-disorder-100566826","NCT06660225","Deep Brain Stimulation for Refractory Obsessive-Compulsive Disorder","Towards Closed Loop Deep Brain Stimulation for Treatment of Refractory Obsessive-Compulsive Disorder","Inclusion Criteria:\n\n* Patients with a diagnosis of obsessive-compulsive disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 criteria\n* Severe OCD assessed by the Yale-Brown Obsessive-Compulsive Scale (YBOCS) with a score of more than 27\n* Refractory OCD; severe symptoms and impairment for more than 5 years despite pharmacological and psychological treatment.\n* Have failed to improve following treatment with at least two serotonin transport inhibitors and one augmenting agent taken for an adequate time period.\n* Having failed to improve despite adequate cognitive behavioral therapy, as evaluated by the study psychiatrist\n* Patients between 22 and 75.\n* Ability to understand and sign written informed consent by the patient.\n\nExclusion Criteria:\n\n* Diagnosis of severe major depression disorder (MDD) with psychotic features.\n* Significant suicidal risk \\[Hamilton Depression scale item 3 (suicide)\\>2\\].\n* Comorbidity with any primary Psychotic Disorder, Post-Traumatic Stress Disorder (PTSD), or Eating Disorder.\n* History of substance or alcohol dependence or abuse in the preceding 12 months.\n* Significant cognitive decline, measured by Mini-Mental State Examination (MMSE \\\u003C26) and Montreal Cognitive Assessment (MoCA; \\\u003C24).\n* Any other current clinical significant neurological disorder or medical illness affecting brain function, other than a tic disorder.\n* Any clinically significant abnormality on preoperative MRI that would affect the safety of the surgical procedure in the opinion of the study neurosurgeon.\n* Any DBS contraindication, infection, coagulopathy, significant cardiac risk factors, or other medical risk factors for surgery.\n* Pregnancy.",{"count":625,"type":23},10,[26],"The goal of this clinical trial is to learn if deep brain stimulation (DBS) works to treat refractory obsessive-compulsive disorder (OCD). The main questions it aims to answer are:\n\n* Assess the effects of the anteromedial sub-thalamic nucleus (amSTN)stimulation on obsessive\u002Fcompulsive symptoms.\n* Map the amSTN using neuronal responses \\[single unit and local field potentials (LFP) recordings\\] at rest and under high frequency stimulation during surgery.\n* Record chronic brain activity with the implanted pulse generator and look for neuronal signatures correlated with symptom severity.\n\nResearchers will compare active deep brain stimulation to a placebo (sham stimulation) to see if DBS works to treat refractory OCD.\n\nParticipants will:\n\n* Undergo surgery for the implantation of a deep brain stimulation device\n* Follow-up visits every three weeks with study staff\n* 6 month follow-up for the next 2-3 years after first year of study participation is complete",[29],[630,631,632],"Obsessive","Compulsive","Deep Brain Stimulation","2026-04-30",{"date":609,"type":34},{"date":442,"type":23},{"date":637,"type":23},"2031-01",{"name":639,"class":41},"Nader Pouratian",{"id":641,"slug":642,"hasResults":12,"nctId":643,"briefTitle":644,"officialTitle":645,"acronym":4,"eligibilityCriteria":646,"healthyVolunteers":12,"sex":18,"minAge":226,"maxAge":522,"enrollmentInfo":647,"targetDuration":4,"studyType":24,"phases":649,"briefSummary":650,"conditions":651,"keywords":652,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":655,"lastUpdatePostDateStruct":656,"startDateStruct":658,"completionDateStruct":660,"leadSponsor":662,"locationsCount":79},"100436043","cortical-stimulation-to-treat-obsessive-compulsive-disorder-100436043","NCT04958096","Cortical Stimulation to Treat Obsessive Compulsive Disorder","Adjunct Cortical Stimulation With Deep Brain Stimulation (DBS) to Treat Obsessive Compulsive Disorder (OCD)","Inclusion Criteria:\n\n* Ability to give informed consent for the study\n* Age 22-75\n* Clinical diagnosis of OCD\n* Documented duration of OCD of at least 5 years\n* OCD rated as severe or extreme illness (YBOCs ≥ 28)\n* Has failed to improve following treatment with at least two selective serotonin reuptake inhibitors (SSRIs), clomipramine, and augmentation with antipsychotics\n* Has not responded to adequate trials of cognitive behavior therapy (exposure and response prevention)\n* Has not responded adequately to TMS treatment for OCD if it is reasonably available to the patient\n\nExclusion Criteria:\n\n* Has hoarding as a primary subclassification of OCD according to DSM-4\n* Has another severe psychiatric disorder (personality disorder, psychotic\u002Fbipolar disorder, etc) or substance abuse issues\n* Is pregnant\n* Has an abnormal MRI assessed by the team or has a neurological condition requiring an MRI in the future\n* Has a cognitive disorder or dementia\n* Is at imminent risk for suicide based upon Suicide Severity Rating Scale (SSRS) or has ever attempted suicide\n* Inability to comply with study follow-up visits\n* Major comorbidity increasing the risk of surgery (prior stroke, severe hypertension, severe diabetes, or need for chronic anticoagulation other than aspirin)\n* Allergies or known hypersensitivity to materials in the Activa systems (i.e. titanium, polyurethane, silicone, polyethermide, stainless steel).\n* Previous cranial ablative or deep brain stimulation surgery.\n* Patients may be excluded from enrollment due to a condition that, in the judgement of the PI, significantly increases risk or reduces significantly the likelihood of benefit from DBS.",{"count":648,"type":23},15,[26],"The purpose of this study is to identify abnormal brain signals associated with Obsessive Compulsive Disorder (OCD) and psychiatric symptoms and to investigate novel therapeutic stimulation sites. While treating OCD with standard deep brain stimulation (DBS) therapy, the investigators will also monitor the activity of the anterior cingulate and prefrontal cortex, a region known be involved with OCD, decision making, and emotion regulation, and the investigators will identify abnormal activity corresponding to the severity of a patient's OCD. The investigators will also investigate whether it is possible for stimulation delivered to these parts of the brain can improve OCD symptoms. These investigations have the potential to aid in the development of improved forms of DBS that can better target abnormal OCD brain signatures in the future.\n\nThe investigators will implant a cortical electrode in addition to the ALIC DBS electrode and connect these to an implantable pulse generator that care store field potential data (Medtronic Percept). The decision whether the lead is placed in the prefrontal or cingulate cortex bilaterally will be based upon considerations of the surgical risks for a particular patient based upon their anatomy and the required surgical approach.\n\nAt multiple time points post-implantation up to 2 years, in our clinic or patient's homes, cortical and subcortical signals will be recorded. Data will be collected while patient are resting or engaged in symptom provocation tasks, emotional\u002Fcognitive tasks while cortical stimulation is on and off. In addition to brain signal recordings, symptoms will be assessed using validated questionnaires and tasks to allow identification of neurophysiological correlates of OCD symptoms.",[29],[130,58,653,654],"Obsessive thoughts","Compulsions","2026-04-27",{"date":657,"type":34},"2026-05-01",{"date":659,"type":34},"2021-08-01",{"date":661,"type":23},"2026-08-01",{"name":663,"class":41},"Andrew Moses Lee, MD, PhD"]